

DCAT

TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

Tuesday
July 12, 2016

DCAT
sharpSounding
2016
EDUCATION FORUMS • NETWORKING KEYNOTE • SPEAKER

1. [Monsanto Rejects Bayer's \\$62 Billion Acquisition Proposal; Open To Talks](#)

Monsanto Company has rejected Bayer AG's proposal to acquire Monsanto for \$62 billion but has said that it is open to further discussions. Bayer's move to acquire Monsanto is the first large-scale acquisition for Bayer since its strategic decision to be a pure-play life sciences company with three main business areas: pharmaceuticals, crop science, and consumer healthcare. [Read More](#)

2. [Sanofi Seeks To Replace Medivation's Board in Its \\$9.3 Billion Takeover Bid](#)

Sanofi has filed preliminary consent solicitation materials with the US Securities and Exchange Commission seeking to remove and replace each member of the Board of Directors of the biopharmaceutical company, Medivation, as Sanofi continues a plan to acquire Medivation in a takeover bid of \$9.3 billion, a move that Medivation has thus far twice rejected. [Read More](#)

3. [Sanofi Makes Executive Changes](#)

Sanofi Chief Executive Officer Olivier Brandicourt has announced a number of changes to the company's Executive Committee, supporting Sanofi's recently announced 2020 Strategic Roadmap. The moves include the departure of the company's executive vice president of its diabetes and cardiovascular business, the company's largest therapeutic franchise with 2015 revenues of EUR 7.58 billion (\$8.48 billion). [Read More](#)

4. [Gilead Sciences Makes Senior Management Changes](#)

Gilead Sciences has made two appointments to the company's senior leadership team. Kevin Young has been appointed chief operating officer with responsibility for Gilead's worldwide commercial organization, including facilities and operations. Martin Silverstein, MD, has been appointed executive vice president, strategy. [Read More](#)

5. [Janssen, MacroGenics Sign \\$740 Million Bispecific Antibody Pact](#)

MacroGenics, a clinical-stage biopharmaceutical company developing monoclonal antibody-based cancer therapeutics, has formed a global collaboration and license agreement with Janssen Biotech for a preclinical bispecific molecule in a deal valued up to \$740 million. MacroGenics has a proprietary platform to allow manufacturing using a conventional antibody platform without having to genetically modify T cells from individual patients as required with chimeric antigen receptor (CAR) T cells. [Read More](#)

6. [FDA Accepts Samsung Bioepis' BLA for a Biosimilar of Remicade](#)

The FDA has accepted for review Samsung Bioepis' biologics license application for a biosimilar candidate referencing Johnson & Johnson's (J&J) Remicade (infliximab). Remicade was one of J&J's

top-selling pharmaceuticals with global 2015 sales of \$6.56 billion. It is the first biosimilar filed for regulatory approval in the US as part of the biosimilar collaboration formed in 2013 between Samsung Bioepis and Merck & Co. [Read More](#)

7. EMA Accepts Sandoz's MAA for a Biosimilar of Roche's MabThera

The European Medicines Agency has accepted Sandoz's marketing authorization application for a biosimilar to Roche's European Union (EU)-licensed MabThera (rituximab). Biosimilar rituximab is part of Sandoz' growing biosimilar oncology and immunology portfolio. The oncology portfolio includes two marketed products (filgrastim and epoetin-alfa) and biosimilar candidate pegfilgrastim, which is under regulatory review in the US and EU. This is the tenth regulatory biosimilar filing that the company plans to submit over a three-year period (2015-2017). [Read More](#)

8. GSK, Avalon Ventures Form New Immunotherapy Company

Avalon Ventures, a private equity firm, and COI Pharmaceuticals, a pharmaceutical venture entity, have announced the formation of PDI Therapeutics to develop immuno-oncology therapies. PDI Therapeutics is the eighth company formed by Avalon and GlaxoSmithKline (GSK) and the first company formed under their expanded collaboration that was announced in November 2015. [Read More](#)

9. Italian API Producer Olon Acquires INFA Group

Olon SpA, a manufacturer of active pharmaceutical ingredients (APIs) and subsidiary of the Milan, Italy-based P&R Group, a chemical/pharmaceutical company, has agreed to acquire INFA Group, an API and fine chemicals manufacturer headquartered in Milan, Italy. Olon has five manufacturing sites in northern Italy with more than 800 employees. INFA Group, with more than 400 employees, has two manufacturing sites in Italy and one in Spain. [Read More](#)

10. Colorcon To Acquire BASF Excipient Product Line

Colorcon has agreed to acquire BASF's Kollicoat IR Coating Systems product line, including the current customer business, inventory and relevant know-how. The addition of the Kollicoat IR Coating Systems complements Colorcon's existing film coating product lines. The companies previously formed a cooperation in October 2014 for using the immediate-release coating polymer Kollicoat IR for Colorcon's formulated ready-to-use coatings. [Read More](#)

****Upcoming DCAT Event Preview****

Moving Beyond Traditional Paradigms in Sourcing and Procurement

How can pharmaceutical companies and suppliers move beyond traditional paradigms in sourcing and procurement and advance more strategic partnerships to meet desired business goals? More collaborative and strategic partnerships are a win-win for pharmaceutical companies and their suppliers, but how do companies overcome challenges in realizing their potential? **DCAT Sharp Sourcing 2016**, to be held Tuesday, July 12, in New Brunswick, New Jersey, provides some answers. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org